Organization Overview
Alternative names
burosumab-twza (crysvita) (2018)
granisetron (kytril) (2008)
istradefylline (Nourianz) (2019 NDA)
mogamulizumab (poteligeo) (2018 NDA)
toremifene (fareston) (1997 NDA)
Carcinoma (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Transitional Cell (Phase 1)
Dermatitis (Phase 2)
Dermatitis, Atopic (Phase 2)
Eczema (Phase 2)
Familial Hypophosphatemic Rickets (Phase 3)
Gastroparesis (Phase 2)
Hypophosphatemia (Phase 3)
Leukemia (Phase 1)
Leukemia, Myeloid (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Liver Diseases (Phase 1)
Lung Neoplasms (Phase 1)
Movement Disorders (Phase 2)
Myelodysplastic Syndromes (Phase 1)
Parasomnias (Phase 2)
Parkinson Disease (Phase 3)
Preleukemia (Phase 1)
Psychomotor Agitation (Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 2)
Restless Legs Syndrome (Phase 2)
Sleep Wake Disorders (Phase 2)
Syndrome (Phase 2)
Thrombocytopenia (Phase 2)